Reader Comments

Post a new comment on this article

Considering that interferons (Avonex, Betaseron and Rebif) have the same efficacy is a mistake

Posted by AClapin on 25 Nov 2014 at 08:57 GMT

Interferons in multiple sclerosis have not the same efficacy.
A recent Cochrane review concluded that Avonex had a negatve benefit/risk ratio : http://www.ncbi.nlm.nih.g...
Prior to this publication, I published a demonstration of the attrition bias of the MSCRG study which is the only study used for Avonex approval in multiple sclerosis.
Comparing interferons beta as a whole to another product is misleading for patients. Such studies are pushing patients to second line products with their increased risks. They also validate the false argumentary : my product is better to Avonex, so it is better that all interferons. Most of the recent comparisons versus interferon are against Avonex...

No competing interests declared.